OBJECTIVE: Treatment of gestational diabetes (GDM) is associated with improved pregnancy outcomes. Obstacles to taking prescribed medications can lead to non-compliance. The objective was to determine the challenges that lead to low medication adherence and whether this increases the rate of adverse pregnancy outcomes in women with GDM. STUDY DESIGN: A prospective, observational study was performed of women with GDM treated with metformin, glyburide or insulin at a tertiary care center. Women greater than 16 weeks gestation and treated for a minimum of 2 weeks were included. Women with pre-DM were excluded. Women completed a validated survey, MMAS-8 (low: score <6 and high: score 7-8), to identify women with low and high medication adherence. Information resulting in medication compliance was collected. The primary outcome was neonatal birth weight >4,000g. Secondary outcomes included factors with medication adherence, adherence rates for each medication and neonatal outcomes. RESULTS: Of 79 women who met study criteria, 42 reported high and 37 reported low adherence. Birth weight >4,000g were similar in each group, (low: 16.2% vs. high: 7.1%, p ¼ 0.292). Women prescribed metformin had the highest rate of high adherence (38.1%) and women on glyburide had the highest rate of low adherence (46%). The rate of neonatal hypoglycemia was significantly higher in women with low adherence compared to high adherence, (low: 70.3% vs high 42.9%, p ¼ 0.023). There were similar rates of induction of labor, cesarean section, NICU admissions, and neonatal respiratory complications. There were no cases of shoulder dystocia, Erb's palsy, or major neonatal morbidities. Obstacles to medication adherence were documented in 14% of women including prescription error, insurance difficulties and delay in dispensing the medications. Adverse effects to medication were reported in 10-20% of women.
CONCLUSION:
Although there were no differences in neonatal birthweight between groups, low medication adherence was associated with neonatal hypoglycemia. Challenges to compliance with prescribed medications occurred in 14% of GDM women and up to 1 in 5 women reported a medication side effects. Further studies are needed to investigate patient-specific and system-level strategies to improve medication adherence in women with GDM.
397 Neonatal risks associated with maternal glucose intolerance in the absence of gestational diabetes LGA birthweight >97%ile, hypoglycemia requiring treatment, and shoulder dystocia. Bivariate analyses compared women with glucose intolerance to women without glucose intolerance across demographic and clinical factors (Table 1) . Odds ratios for the outcome of interest were compared between exposed and unexposed women using multivariable logistic regression to adjust for possible confounders ( OBJECTIVE: While early gestational diabetes (GDM) screening has been expanded to a larger patient proportion, no standard protocol for follow-up after normal early screening has been adopted. Uncertainty exists as to whether patients should be re-screened at 24-28 weeks and, if so, which test (1-hour or 3-hour) should be performed at that time. In women who had normal early GDM screening, we evaluated the results of subsequent GDM screening and diagnostic tests at 24-28 weeks to determine the optimal approach to follow-up. STUDY DESIGN: Planned secondary analysis of an RCT examining the clinical utility of early GDM screening. Pregnant women <20 weeks GA with a BMI >30 kg/m 2 were randomized to GDM screening at 14-20 wks (early) versus 24-28 wks (routine). Screening for GDM included a 50-g, 1-hr glucose challenge test (1-hr GCT) followed by a 100-g, 3-hr glucose tolerance test (3-hr GTT) if 1-hr GCT was > 135 mg/dL. Diagnosis of GDM was made using Carpenter-Coustan criteria. Those with negative early screening were re-screened at 24-28 wks, starting with repeat 1-hr GCT, regardless of the early GCT results. Women with pregestational diabetes, major medical problems (cardiac, hematologic), steroid use, bariatric surgery, and prior cesarean were excluded from the initial RCT. RESULTS: Of the 397 who underwent early 1-hr GCT screening in the RCT, 29 (7.3%, 95% CI 4.9-10.3) received a diagnosis of GDM following 3-hr GTT at 14-20 weeks. Of the 85 women with an elevated early 1-hr GCT but normal 3-hr GTT, 45 (52.9%, ) again had a screen-positive 1-hr GCT when repeated at 24-28 wks, and 22 (48.9%, 95% CI 33.7-64.2) of these were diagnosed with GDM on 3-hr GTT. Among the women who initially passed the early 1-hr GCT, only 9 (3.2%, 95% CI 1.5-6.0) were ultimately diagnosed with GDM during re-screening at 24-28 weeks GA. CONCLUSION: Only half of women with an abnormal early 1-hr GCT but normal early 3-hr GTT required a second 3-hr GTT. Given the time and resources required for the 3-hr GTT, we recommend repeating the 1-hr GCT in lieu of proceeding directly to the 3-hr GTT for screening at 24-28 wks. Additionally, among women with a normal early 1-hr GCT, only 3% were ultimately diagnosed with GDM on repeat screening at 24-28 wks; the need for re-screening this population at 24-28 wks should be reconsidered. 
